What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?

Diabetes, Obesity and Metabolism

Volumn 15, Issue S2, 2013, Pages 17-25

  Zenari, L ^a   Marangoni, A ^b  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b Ospedale San Bassiano   (Italy)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Drug therapy; Glucagon like peptide 1 analogues; Glycaemic variability; Incretins; Lifestyle; Type 2 diabetes

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETIC PATIENT; DIET RESTRICTION; DIETARY INTAKE; DRUG SAFETY; FRACTURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCEMIC INDEX; GLYCEMIC VARIABILITY; HEART FAILURE; HUMAN; HYPERINSULINISM; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRESCRIPTION; REVIEW; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

DIPEPTIDYL PEPTIDASE-4 INHIBITORS; DRUG THERAPY; GLUCAGON-LIKE PEPTIDE-1 ANALOGUES; GLYCAEMIC VARIABILITY; INCRETINS; LIFESTYLE; TYPE 2 DIABETES;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; PHYSICIAN'S PRACTICE PATTERNS; POSTPRANDIAL PERIOD; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84883216801     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12143     Document Type: Review

References (66)

1. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl. 1): 1-68.
2. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008; 31(Suppl. 1): S12-54.
3. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007; 30: 2399-2400.
4. Slama G, Elgrably F, Sola A, Mbemba J, Larger E. Postprandial glycaemia: a plea for the frequent use of δ postprandial glycaemia in the treatment of diabetic patients. Diabetes Metab 2006; 32: 187-192.
5. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
6. Liu AG, Most MM, Brashear MM, Johnson WD, Cefalu WT, Greenway FL. Reducing the glycemic index or carbohydrate content of mixed meals reduces postprandial glycemia and insulinemia over the entire day but does not affect satiety. Diabetes Care 2012; 35: 1633-1637.
7. Bao J, Atkinson F, Petocz P, Willett WC, Brand-Miller JC. Prediction of postprandial glycemia and insulinemia in lean, young, healthy adults: glycemic load compared with carbohydrate content alone. Am J Clin Nutr 2011; 93: 984-996.
8. Fonda SJ, Jain A, Vigersky RA. A head-to-head comparison of the postprandial effects of 3 meal replacement beverages among people with type 2 diabetes. Diabetes Educ 2010; 36: 793-800.
9. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008; 51: 249-255.
10. Lawrence RD. The effect of exercise on insulin action in diabetes. Br Med J 1926; 1: 648-650.
11. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008; 31: 173-175.
12. Italian Association of Medical Diabetologists-AMD. Personalisation of therapy in type 2 diabetes. 2011. Available from URL: http://www.aemmedi.it/algoritmi/. Accessed 24 August 2012.
13. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
14. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
15. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
16. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
17. ADVANCE Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
18. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
19. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266-272.
20. Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 185-186.
21. Bennett WL, Maruthur NM, Singh S et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613.
22. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
23. Ferrara A, Lewis JD, Quesenberry CP Jr et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-929.
24. Polonsky KS, Given BD, Hirsch LJ et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239.
25. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
26. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
27. Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-931.
28. Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
29. Raz I, Wilson PW, Strojek K et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-386.
30. Raz I, Ceriello A, Wilson PW et al. Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 2011; 34: 1511-1513.
31. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
33. Wright AD, Cull CA, Macleod KM, Holman RR, UKPDS Group. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6years from diagnosis: UKPDS73. J Diabetes Complications 2006; 20: 395-401.
34. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc 2011; 86: 128-138.
35. Derr R, Garrett E, Stacy GA, Saudek CD. Is HbA(1c) affected by glycemic instability? Diabetes Care 2003; 26: 2728-2733.
36. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
37. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997; 40: 205-211.
38. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
39. Aschner P, Kipnes MS, Lunceford JK et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
40. Scott R, Herman H, Zhao P et al. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes. Diabetologia 2005; 48(Suppl. 1): A287-A288.
41. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186-193.
42. Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011; 13: 699-703.
43. Monnier L, Colette C, Comenducci A, Vallée D, Dejager S. Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes Technol Ther 2012; 14: 943-950.
44. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28: 1176-1181.
45. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012; 11: 92.
46. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24: 79-83.
47. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012; 35: 2076-2082.
48. Guerci B, Monnier L, Serusclat P et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012; 38: 359-366.
49. Avogaro A. Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83). J Diabetes Complications 2011; 25: 352-353.
50. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18.
51. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
52. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688.
53. Alba M, Sheng D, Guan Y et al. Sitagliptin 100mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Curr Med Res Opin 2009; 25: 2507-2514.
54. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009; 52: 1231-1246.
55. He H, Tran P, Yin H et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009; 37: 536-544.
56. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation 1997; 96: 1750-1754.
57. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948-2961.
58. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011; 13: 55-64.
59. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27: 362-372.
60. Registro farmaci anti-diabetici sottoposti a monitoriggio. Rapporto farmaci incretino-mimetici e DPP-4 inibitori. Firenze 2010. Available from URL: http://antidiabetici.agenziafarmaco.it/incretine.pdf. Accessed 23 February 2013.
61. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
62. Schwartz SL, Ratner RE, Kim DD et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008; 30: 858-867.
63. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.
64. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther 2009; 11: 339-344.
65. Irace C, Fiorentino R, Carallo C, Scavelli F, Gnasso A. Exenatide improves glycemic variability assessed by continuous glucose monitoring in subjects with type 2 diabetes. Diabetes Technol Ther 2011; 13: 1261-1263.
66. Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther 2011; 13: 1139-1144.